口服疗法作为免疫介导炎症疾病的新兴治疗方式:叙述性综述
Linda Stein Gold1, Kilian Eyerich2, Joseph F Merola3
1Department of Dermatology, Henry Ford Health, Detroit, MI, USA. lstein1@hfhs.org.
Advances in therapy
|May 29, 2025
概括
伊科特罗金拉是一种新型口服,针对免疫介导炎症性疾病 (IMIDs) 的互白素-23信号传递. 牛皮的早期研究显示出有希望的疗效和安全性,解决了对口服治疗的未满足需求.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
背景情况:
- 免疫媒介性炎症性疾病 (IMIDs),如牛皮,牛皮性关节炎和炎症性肠病,涉及慢性炎症.
- 目前的全身治疗包括可注射单克隆抗体 (mAbs) 和口服小分子,但口服选择往往缺乏有效性或有耐受性问题.
- 对于IMIDs有效的口服疗法有着显著的未满足的需求.
研究的目的:
- 为了评估icotrokinra的疗效和安全性,该药物是第一类针对性口服类抑制剂,可以抑制插白素-23 (IL-23) 信号传递.
- 评估icotrokinra作为治疗中度至重度牛皮和其他IMID的口服治疗的潜力.
主要方法:
- 一项对患有中度至重度牛皮的成年人进行的2b期研究评估了与安慰剂相比,icotrokinra的剂量反应效应.
- 一项扩展研究对患者进行了52周的随访,以评估持续的疗效和安全性.
主要成果:
- 在牛皮患者中,Icotrokinra在第16周表现出与安慰剂相比具有显著的剂量反应效应.
- 该药物表现出可容忍的安全性,持续的皮肤清除观察到52周.
- 在延伸研究期间没有发现任何安全信号.
结论:
- 伊科特罗金拉是一种有前途的向性口服类药物,用于治疗IMID,特别是在牛皮中显示出有效性.
- 它对IL-23信号的选择性抑制和良好的安全性概况解决了对更好的口服疗法的需求.
- 目前正在进行的第二期和第三期试验将进一步确定其在牛皮,牛皮关节炎和性结肠炎中的治疗潜力.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Microorganisms in Medicine and Therapeutics
382
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
382
Inflammatory Response
8.6K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240


